Concurrent chemoendocrine therapy in patients with prevailing breast cancer

Summary. Aim of the study: to compare the effectiveness of different regimes of palliative therapy using tablet forms of drugs in patients with hormone-dependent Her-2/neu negative prevalent breast cancer (BC). We provided information about the outcomes of 96 patients with prevalent BC who were randomized to three groups and treated exceptionally tablet form drugs. The first group (A) 33 patients were involved, which is intended bull palliative endocrine therapy with aromatase inhibitor anastrozole 1 mg daily. For one course of therapy in this group of patients considered time period of 21 days. The second group (C+Ca) included 31 patients in whom therapy is intended bull capecitabine (2500 mg/m per day from 8 to 21 day) with cyclophosphamide (100 mg daily from 1 to 14 days 21-days cycle of therapy). The third group (C+A) included 32 patients assigned to therapy with capecitabine (2500 mg/m per day from the 1 to the 14 day of the 21-day cycle of therapy) in combination with a daily intake of anastrozole 1 mg – concurrent chemoendocrine therapy. We determined duration of progression-free period — the time from start of treatment in the study to detect the first signs of tumor progression against the background of cytostatic therapy (the method of Kaplan — Meier) and toxic manifestations of the therapy. The average duration of progression-free period in patients receiving capecitabine concurrent chemoendocrine therapy with anastrozole (14,3±1,9 months) longer than the corresponding figure in groupe of patients taking mono endocrine therapy with anastrazol (9,8±1,2 months) or combine tablet form cytostatic therapy with cyclophosphamide and capecitabine (10,8±1,3 months). Disease-free survival determined by Kaplan — Meier higher in patients treated with capecitabine combined with anastrazole chemoendocrine therapy, compared with patients receiving anastrozole therapy alone or combination capecitabine with cyclophosphamide (r≤0,005). The frequency of adverse events in patients who received different types of palliative therapy tablets was almost the same. There were toxic manifestations I and II degree of toxicity. The tablet can be considered palliative concurrent chemoendocrine therapy option choice therapy in patients with hormone dependent Her-2/neu negative prevalent BC through adequate efficacy, favorable toxicity profile and the possibility of long-term outpatient use.